TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02617 TRANSTHERA-B

Closed 12-22 16:08:08

168.700

+4.800

+2.93%

High173.000	Low160.300	Vol793.50K
Open166.300	D1 Closing163.900	Amplitude7.75%
Mkt Cap66.97B	Tradable Cap50.89B	Total Shares397.00M
T/O133.67M	T/O Rate0.26%	Tradable Shares301.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":168.7,"timestamp":1766390888680,"preClose":163.9,"halted":0,"volume":793500,"delay":0,"floatShares":301666673,"shares":397000000,"eps":-0.7959622494321188,"marketStatus":"Closed","change":4.8,"latestTime":"12-22 16:08:08","open":166.3,"high":173,"low":160.3,"amount":133672500,"amplitude":0.077486,"askPrice":168.8,"askSize":1000,"bidPrice":168.7,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.6866716890966799,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":163.9,"openAndCloseTimeList":[[1766367000000,1766376000000],[1766379600000,1766390400000]],"volumeRatio":0.843817,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"2592131490","title":"BUZZ-HK-listed TransThera climbs on new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131490","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592131490?lang=en_us&edition=fundamental","pubTime":"2025-12-19 10:47","pubTimestamp":1766112441,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed TransThera climbs on new drug application ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences  Inc 2617.HK climb 3% to HK$173    ** Stock on course to end the week up 5.9%, snapping three straight weekly losess** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration ** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 74.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL1N3XP02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592136484","title":"New Drug Application for Tinengotinib Tablets Accepted by the National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592136484?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:47","pubTimestamp":1766108828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA5ZSDYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1146650124","title":"TRANSTHERA-B (02617): New Drug Application for Tinengotinib Tablets Accepted by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1146650124","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146650124?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:24","pubTimestamp":1766103876,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the new drug application for Tinengotinib Tablets has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592389831","title":"China's NMPA Accepts New Drug Application for Transthera Sciences' Tinengotinib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2592389831","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592389831?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:12","pubTimestamp":1766103161,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. announced that its new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation of the National Medical Products Administration in China. The application pertains to the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma who have received at least one prior systemic treatment and FGFR inhibitor treatment. Tinengotinib tablets have previously been included in lists for priority review and breakthrough therapy designation for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2CjDmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2592138679","title":"Transthera Sciences (Nanjing) Inc - Nmpa Accepts New Drug Application for Tinengotinib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2592138679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592138679?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:11","pubTimestamp":1766103111,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO16A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1103397138","title":"TRANSTHERA-B (02617) Announces Exploratory Phase 2 Clinical Results of Core Product Tinengotinib for Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1103397138","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103397138?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:08","pubTimestamp":1765973296,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the exploratory Phase 2 clinical results of its core product, tinengotinib, for cholangiocarcinoma conducted in the U.S. were recently published in *The Lancet...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2592994290","title":"Transthera Sciences Reports Positive Phase 2 Results for Tinengotinib in Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994290","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994290?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:55","pubTimestamp":1765972506,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the publication of clinical results from a US-based Phase 2 trial evaluating its core product, Tinengotinib, in patients with cholangiocarcinoma . The results were published in The Lancet Gastroenterology and Hepatology. The study involved patients with FGFR2 fusion-positive CCA who had either primary or acquired resistance to prior FGFR inhibitor therapy, as well as patients with other FGFR alterations or FGFR wild-type tumors. Tinengotinib demonstrated clinical activity in patients with FGFR2 fusion-positive CCA with acquired resistance to FGFR inhibitors, as well as in other FGFR-altered subtypes. The company notes there is no assurance that Tinengotinib will ultimately be successfully developed and marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL7klhrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1189029586","title":"HK Movers | HK's Biotech Shares Soar. TransThera up 19%; JOINN up 11%; Xuanzhu Bio up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189029586","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189029586?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:43","pubTimestamp":1765943020,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.TransThera rose 19%; JOINN rose 11%; Xuanzhu Bio up 6%; Remegen, Wuxi Bio up 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"56cee07d353081b3259b34f98f1a012b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","02575","06127"],"gpt_icon":0},{"id":"1121164453","title":"HK Stock Movement | TRANSTHERA-B (02617) Surges Nearly 14% After Announcing Positive Clinical Results for Tinengotinib in The Lancet Sub-Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1121164453","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121164453?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:38","pubTimestamp":1765939096,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) surged nearly 14%, rising 13.85% to HKD 166.1 by the time of writing, with a trading volume of HKD 112 million. The company recently announced that the exploratory Phase 2...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2589868705","title":"TransThera Sciences Reports Positive Phase 2 Results for Tinengotinib in Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589868705","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589868705?lang=en_us&edition=fundamental","pubTime":"2025-12-05 12:32","pubTimestamp":1764909130,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib  in patients with cholangiocarcinoma . The findings have been published in The Lancet Gastroenterology and Hepatology. The multicenter, open-label Phase 2 trial enrolled patients with FGFR2 fusion-positive CCA who had demonstrated resistance to prior FGFR inhibitor therapy, as well as patients with other FGFR alterations and FGFR wild-type tumors. Tinengotinib demonstrated clinical activity, including durable responses and meaningful clinical benefit, in patients with FGFR2 fusion-positive CCA with acquired resistance to FGFR inhibitors, as well as in other FGFR-altered subtypes. The results support further clinical investigation in a Phase 3 registration study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL9BLJHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2589865231","title":"TransThera Sciences (Nanjing) (SEHK:2617): Assessing a Lofty Valuation After a 200% Three-Month Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865231?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:23","pubTimestamp":1764901415,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in.\nSee our latest analysis for TransThera Sciences (Nanjing).\nThat surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2588008606","title":"BUZZ-TransThera climbs on product inclusion in priority review list","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588008606?lang=en_us&edition=fundamental","pubTime":"2025-12-04 13:38","pubTimestamp":1764826681,"startTime":"0","endTime":"0","summary":"BUZZ-TransThera climbs on product inclusion in priority review list  ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences  Inc 2617.HK climb 3.3% to HK$199.3, on track for the biggest one-day pct rise since November 21** Stock touches the highest level since December 1, on track for the second session of gains** TransThera said its Tinengotinib tablets, for treatment of adults with metastatic cholangiocarcinoma, have been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration  ** Stock, which debuted on June 23, up 1,387% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 78.4%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL1N3XA04Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1153831903","title":"TRANSTHERA-B (02617): Tinengotinib Tablets Approved for Priority Review by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1153831903","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153831903?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:16","pubTimestamp":1764753372,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that Tinengotinib tablets have been approved for inclusion in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2588011148","title":"Tinengotinib Wins Priority Review by China’s National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011148","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011148?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:11","pubTimestamp":1764753090,"startTime":"0","endTime":"0","summary":"Transthera Sciences  Inc. announced that its Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration  of China. The proposed indication is for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma  who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib was also granted Breakthrough Therapy Designation by the NMPA for the treatment of CCA. No other organizations are mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL53n3bG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1103323002","title":"TransThera Sciences (Nanjing), Inc. (02617) Announces Monthly Return on Movements in Securities for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1103323002","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103323002?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:43","pubTimestamp":1764661397,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (02617) published its Monthly Return on Movements in Securities for the period ended 30 November 2025. According to the announcement, the company's authorized...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1118952429","title":"HK Movers | HK's Biotech Shares Soar. Beigene up 4%; TransThera Sciences up 3%; Hengrui Pharma up 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118952429","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118952429?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:46","pubTimestamp":1763430415,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Tuesday.Beigene rose 4%; TransThera Sciences up 3%; Hengrui Pharma rose 2%; Innovent Biologics, Ascletis rose 1%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"502d1227e9e803b590cafd45bb18d9f3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06160","02617"],"gpt_icon":0},{"id":"1163925095","title":"Hong Kong Regains Top Spot in Global IPO Fundraising with Insights from Value Partners Founder Cheah Cheng Hye","url":"https://stock-news.laohu8.com/highlight/detail?id=1163925095","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163925095?lang=en_us&edition=fundamental","pubTime":"2025-11-10 14:12","pubTimestamp":1762755140,"startTime":"0","endTime":"0","summary":"Hong Kong's IPO market has delivered a stellar performance this year, reclaiming its position as the global leader in fundraising, driven by several high-profile listings on the Hong Kong Stock...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPO","BK1161","LU1960683339.HKD","BK1116","00806","LU1807302812.USD","HEXmain","LU1993786604.SGD","02259","BK1610","02617","03750","BK1198","BK1156"],"gpt_icon":1},{"id":"1186579983","title":"Southbound Capital Flow Data (T+2) | November 10","url":"https://stock-news.laohu8.com/highlight/detail?id=1186579983","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186579983?lang=en_us&edition=fundamental","pubTime":"2025-11-10 07:32","pubTimestamp":1762731166,"startTime":"0","endTime":"0","summary":"On November 5, the top three stocks by net southbound capital inflows were **CSOP Hang Seng Tech ETF (03033)**, **Alibaba-W (09988)**, and **Xiaomi-W (01810)**, with inflows of **HKD 1.286 billion**,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1590","00308","LU0456827905.SGD","LU1568876251.USD","SG9999001051.SGD","LU0873338254.USD","LU0165289439.USD","LU0784639295.USD","LU0348783662.USD","LU0314109678.HKD","81810","LU0348766576.USD","LU1023057109.AUD","LU1880383440.USD","LU0823397285.USD","LU1880383366.USD","LU1328277881.USD","LU0049853897.USD","SG9999001689.USD","LU0231483743.USD","LU1235295612.USD","LU1642822792.SGD","LU0327786744.USD","BK1510","LU0890818403.SGD","IE0032431581.USD","00966","LU0054450605.USD","LU0345780521.USD","00981","02899","SG9999007991.SGD","LU0251144936.SGD","LU1051768304.USD","BK1523","LU0264606111.USD","LU2097828631.EUR","LU2125910500.SGD","KSTmain","LU0197773673.USD","LU1720051017.SGD","LU2097828714.EUR","LU0417516902.SGD","LU0043850808.USD","LU0708995153.HKD","BK1552","81024","HK0000306685.HKD","LU1655091459.SGD","LU0531970944.HKD","BK1558","LU0594300179.USD","01798","HK0000165453.HKD","LU0051755006.USD","LU0633140560.USD","LU0823397103.USD","LU0823426480.USD","BK1185","BK1615","LU1242518857.USD","LU0821914370.USD","LU0588546209.SGD","LU0607220059.USD","01347","00763","IE0034224299.USD","LU0029874905.USD","LU0348783233.USD","LU0117844026.USD","BK1586","LU0737861772.HKD","LU0348827113.USD","LU1316542783.SGD","LU1880398471.USD","LU0979878070.USD","LU0449509016.USD","01024","LU0130103400.USD","BK1104","LU1688375341.USD","LU1439103000.SGD","80883","LU0348825331.USD","01810","BK1140","LU1282649141.HKD","LU0516422952.EUR","LU0345776255.USD","LU0029875118.USD","00257","LU0588545730.USD","LU0593848301.USD","SG9999002562.SGD","LU0266512473.USD","02039","LU0441854154.USD","LU0163747925.USD","00939","BK1193","LU0608807433.USD","LU0348816934.USD","BK1567","LU0823413587.USD","BK1164","LU0130518102.USD","LU0823426308.USD","LU0455707207.USD","BK1514","LU0396098781.USD","LU0634319403.HKD","00639","LU0326950275.SGD","BK1506","HXXD.SI","LU0128522744.USD","SG9999001226.SGD","HK0000306701.USD","BK1589","LU0169518387.USD","BK1237","HK0000320223.HKD","BK1131","LU0072462343.USD","LU1303224171.USD","LU2039709279.SGD","LU1188198961.HKD","IE00BZ08YS42.EUR","03866","BK1507","LU0640798160.USD","LU0531971595.HKD","LU0868486357.SGD","LU0214875030.USD","LU0128522157.USD","LU1064130708.USD","BK1225","LU0791591158.USD","LU0143863198.USD","LU0417516571.SGD","SG9999001069.SGD","LU1366334651.USD","SG9999001093.SGD","00991","LU0918141705.HKD","LU2778985437.USD","03143","LU0261950983.USD","LU0862451837.USD","LU1282648689.USD","LU1497733631.SGD","LU0261947096.USD","BK1526","BK1556","LU2045819591.USD","02192","BK1170","LU0541501648.USD","LU0049112450.USD","LU0359201612.USD","BK1161","LU1044876610.USD","LU0106252389.USD","LU2476274720.SGD","LU3063872942.SGD","00990","LU0228659784.USD","IE00BPRC5H50.USD","IE0003895053.USD","IE00B5MMRT66.SGD","LU0918141887.USD","LU1634259557.SGD","02617","LU1993786604.SGD","LU0348784397.USD","LU0210527791.USD","LU0084288322.USD","01398","LU0700851271.USD","LU0577902538.SGD","LU1769817179.HKD","LU0164880469.USD","LU2148611432.USD","LU2097829019.USD","LU0164872284.USD","02601","LU0228367735.SGD","LU1051769294.HKD","03403","LU0865486749.SGD","LU0244354667.USD","LU0463099449.HKD","LU0054237671.USD","LU0345780281.USD","LU0384037296.USD","LU0516422366.SGD","BK1529","IE00B29SXG58.USD","LU2476274308.USD","LU0320764755.SGD","LU1064131003.USD","LU1323998911.USD","LU2097828805.USD","LU0588545490.SGD","LU0449515922.USD","LU0149721374.USD","LU1568876335.HKD","LU0651947912.USD","BK1123","LU0541502299.USD","LU1880398554.USD","LU0254981946.USD","06869","LU0456846285.SGD","LU1720050803.USD","LU0823413660.USD","00667","LU1224709979.USD","BK1538","LU0329678337.USD","LU0630378692.HKD","BK1189","BK1238","LU2449936058.SGD","BK1560","LU1481107354.HKD","LU0348767384.USD","LU0683595622.HKD","02460","LU0328353924.USD","LU0611395673.USD","LU1497734951.SGD","SGXZ90724238.SGD","LU0898667661.SGD","LU0348814723.USD","LU0370786039.SGD","BK1504","BK1521","IE00BZ08YT58.USD","LU1366334578.USD","SG9999013353.USD","LU0608807946.USD","LU0642271901.SGD","BK1594","BK1528","IE00B0169N27.USD","LU0797268264.HKD","LU0572940350.SGD","LU1115378108.SGD","LU1794554557.SGD","LU0266512127.USD","BK1608","LU0106959298.USD","LU0561508036.HKD","LU2226246903.HKD","01055","LU0791590937.USD","00548","LU0143863784.USD","BK1561","LU0675040207.SGD","LU0588545904.SGD","LU0572939691.SGD","LU1813983027.USD","02800","BK1163","BK1587","09988","LU1224444064.USD","LU1655091616.SGD","BK1200","LU1868837565.USD","LU1831875114.USD","BK1149","LU1282651048.USD","BK1530","LU1211504680.USD","LU1810669033.SGD","00883","IE00B543WZ88.USD","LU0329678170.USD","LU0577902298.EUR","LU0572944931.SGD","02419","BK1136","LU1769817096.USD","LU2242644610.SGD","BK1582","09626","03969","LU0469268626.HKD","LU1328615791.USD","LU0862451753.SGD","LU1808992512.USD","LU0259732245.USD","IE00BVYPNQ40.USD","BK1607","LU1634259391.SGD","BK1618","BK1249","IE00BGV7N243.SGD","LU1548497426.USD","LU1497733557.USD","LU0477156797.USD","BK1584","LU1522347837.USD","LU1770036033.HKD","LU0543330566.HKD","LU2399975544.HKD","00168","BK1578","LU2125910849.SGD","02382","BK1502","LU0516423091.SGD","LU1960683339.HKD","SG9999014674.SGD","LU0348735423.USD","BK1500","LU1807302812.USD","LU0149534421.HKD","LU0348788117.USD","LU1981816686.USD","LU0633140727.USD","BK1154","LU0417516738.SGD","IE00BGHQDM52.EUR","LU0871576103.HKD","LU1515016050.SGD","LU2293587155.HKD","BK1537","LU0140636845.USD","LU1720051108.HKD","LU0196878994.USD","LU0819123356.HKD","LU0011963245.USD","BK1539","IE00BWDBJ730.SGD","LU0762540952.USD","BK1591","LU0307460666.USD","SG9999006514.SGD","IE00B19Z5X02.USD","LU1201861165.SGD","BK1184","LU1105468828.SGD","LU2097828474.EUR","LU0540923850.HKD","LU1504937902.USD","89988","LU1251922891.USD","LU0048388663.USD","LU1242518931.SGD","LU0577902371.SGD","LU0048597586.USD","LU0819121731.USD","LU0096374516.USD","LU1961090484.USD","03033","IE00B0JY6N72.USD","LU0516423174.USD","LU0823038988.USD","LU0577902454.USD","BK1119","SG9999004220.SGD","IE00BYV24P56.USD","LU1956131251.USD","MCHmain","BK1235","LU0577902611.USD","LU1046422090.SGD","LU0708995583.HKD","LU0235996351.USD","BK1095","BK1592","LU2087589342.USD","LU2097828557.USD","HBBD.SI","LU1196710864.SGD","LU0762541174.USD","LU0132412106.USD","LU0287142896.SGD","LU1282651121.HKD","BK1610","LU0831103253.SGD","LU0345775950.USD","SG9999003461.SGD","LU0359202008.SGD","LU0828237940.HKD","BK1517","LU2213484517.USD","LU2357305700.SGD","BK1124","LU1044874839.SGD","SG9999002828.SGD","09636","SG9999000459.SGD","LU2148510915.USD","LU0488056044.USD","LU0823041008.USD","LU0543330483.HKD","LU0320764599.SGD","BK1125","BK1550","LU0648948544.HKD","LU0651946864.USD","LU0737861699.HKD","BK1604","LU2488822045.USD","LU0502904849.HKD","BK1501","LU1282649810.SGD","SG9999006597.SGD","BK1505","BK1595","LU0594300419.USD","LU0229945570.USD","LU0315179316.USD","LU0456854461.SGD","BK1180","BK1198","SG9999002463.SGD","LU0516422440.USD","LU1048484197.HKD","LU0499858602.USD","BK1575","LU0499858438.USD","LU2257852520.SGD","LU0605514214.HKD","LU0762542818.HKD","02273","LU1282649067.USD","LU1719994722.HKD","BK1183","LU1044875133.USD","LU0831093199.SGD","BK1179","IE00BMPRXR70.SGD","LU1048588211.SGD","LU0823039010.USD","LU0589944569.HKD","LU0648000940.SGD","BK1588","LU0650527681.SGD","02015","LU0320764243.SGD","HK0000320264.USD","LU0197773160.USD","LU0117841782.USD","BK1614","LU0047713382.USD","LU0828237510.HKD","IE00BQJZWZ67.USD","LU0039217434.USD","LU0886674414.USD","XIACY","LU0127658192.USD","LU0630378429.USD","IE00B3M56506.USD","IE0008368304.USD","LU0359201885.HKD","LU0210526637.USD","LU2152927971.USD","LU0048580855.USD","LU0823040885.USD","BK1219","LU1048596156.SGD","02828","BK1544","LU0061477393.USD","LU0181495838.USD","BK1142","LU1868838027.USD","SG9999000327.SGD","IE00BMPRXN33.USD","BK1228","LU0856984785.SGD","LU0164865239.USD","LU0106259558.USD","IE00BMCWC346.EUR","LU0173614495.USD","BK1231","LU0315178854.USD","LU0431992006.USD","LU0672654166.SGD","LU0052750758.USD","LU1770034418.SGD","IE00BVYPNP33.GBP","SG9999001903.USD","IE00BZ08YR35.GBP","LU0293314216.USD","LU0348805143.USD","LU0211977185.USD"],"gpt_icon":1},{"id":"1131237438","title":"TRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine","url":"https://stock-news.laohu8.com/highlight/detail?id=1131237438","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131237438?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:20","pubTimestamp":1762129213,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2580201237","title":"TransThera Sciences and Neurocrine Biosciences Announce NLRP3 Inhibitor Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2580201237","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580201237?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:09","pubTimestamp":1762128575,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced a collaboration with Neurocrine Biosciences, Inc. to develop, manufacture, and commercialize NLRP3 inhibitors for multiple diseases. Under the agreement, Neurocrine will have exclusive rights to the NLRP3 portfolio outside Greater China, while TransThera retains rights within Mainland China, Hong Kong, Taiwan, and Macao. The deal includes an upfront payment to TransThera, with the potential for additional milestone payments, bringing the total value up to US$881.5 million. The partnership also features a research collaboration to further advance NLRP3 technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL8p0G4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0154245756.USD","LU2065171311.SGD","BK4139","BK1161","02617","LU0109394709.USD","LU0320765992.SGD","LU2065170008.USD","LU0823416689.USD","LU2324357040.USD","LU2065169927.USD","LU0154245673.USD","NBIX","LU2065171402.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.1918},{"period":"3month","weight":0.0934},{"period":"6month","weight":11.4639},{"period":"ytd","weight":11.4639}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.","exchange":"SEHK","name":"TRANSTHERA-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRANSTHERA-B,02617,TRANSTHERA-B股票,TRANSTHERA-B股票老虎,TRANSTHERA-B股票老虎国际,TRANSTHERA-B行情,TRANSTHERA-B股票行情,TRANSTHERA-B股价,TRANSTHERA-B股市,TRANSTHERA-B股票价格,TRANSTHERA-B股票交易,TRANSTHERA-B股票购买,TRANSTHERA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}